Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin added to classic triple therapy for Helicobacter pylori eradication
2013-001080-23Phase 3Completed
- Sponsor
- Javier P. Gisbert
- Start
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of rifaximin in Helicobacter pylori infection, sponsored by Javier P. Gisbert. Primary endpoint: Helicobacter pylori eradication (intention-to-treat). Started Feb 2014; status: completed.
02
Drugs
rifaximin
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on 2013-001080-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001080-23.